News Related to Union Investment

Related coverage linked through entity extraction aliases.

Novo Nordisk's CagriSema Underperforms Eli Lilly's Zepbound in Head-to-Head Obesity Trial

Feb 20, 2026

Novo Nordisk's next-generation obesity drug CagriSema achieved 23% weight reduction compared to 25.5% for Eli Lilly's tirzepatide in an 84-week trial, sending Novo shares down 15% and erasing over $400 billion in market value since 2024.

Sanofi Ousts CEO Hudson, Appoints Belén Garijo to Fix Drug Pipeline

Feb 13, 2026

Sanofi replaced CEO Paul Hudson with Belén Garijo from Merck KGaA after a stalled turnaround. The company faces pressure to develop drugs to replace blockbuster Dupixent and navigate U.S. vaccine skepticism.